Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation
Dor, Y., Brown, J., Martinez, O. I., & Melton, D. A. (2004) · Nature · doi:10.1038/nature02520 · Cited by 2,219
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Bergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Research works printed but not linked: 113
- Porte Jr, 1991, Banting lecture 1990. β-Cells in type II diabetes mellitus., Diabetes, 40, 166, 10.2337/diabetes.40.2.166 · DOI
- Kahn, 2001, Clinical review 135: the importance of β-cell failure in the development and progression of type 2 diabetes., J Clin Endocrinol Metab, 86, 4047
- Byrne, 1996, Elevated plasma glucose 2 h postchallenge predicts defects in β-cell function, Am J Physiol, 270, E572
- Sakuraba, 2002, Reduced β-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients., Diabetologia, 45, 85, 10.1007/s125-002-8248-z · DOI · Paper page
- Yoon, 2003, Selective β-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea., J Clin Endocrinol Metab, 88, 2300, 10.1210/jc.2002-020735 · DOI · Paper page
- Matveyenko, 2006, β-Cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes., Diabetes, 55, 2106, 10.2337/db05-1672 · DOI · Paper page
- Robertson, 2001, Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis., Diabetes, 50, 47, 10.2337/diabetes.50.1.47 · DOI · Paper page
- Rossetti, 1990, Glucose toxicity., Diabetes Care, 13, 610, 10.2337/diacare.13.6.610 · DOI · Paper page
- Maedler, 2002, Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets., J Clin Invest, 110, 851, 10.1172/JCI200215318 · DOI · Paper page
- Leahy, 1988, Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy., J Clin Invest, 81, 1407, 10.1172/JCI113470 · DOI · Paper page
- Donath, 2004, Decreased β-cell mass in diabetes: significance, mechanisms and therapeutic implications., Diabetologia, 47, 581, 10.1007/s00125-004-1336-4 · DOI · Paper page
- Paty, 2004, Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health Workshop on β Cell Imaging., Transplantation, 77, 1133, 10.1097/01.TP.0000113231.90613.0E · DOI
- Hosokawa, 1996, Mechanism of impaired glucose-potentiated insulin secretion in diabetic 90% pancreatectomy rats. Study using glucagonlike peptide-1 (7-37)., J Clin Invest, 97, 180, 10.1172/JCI118387 · DOI
- Bonner-Weir, 2000, Islet growth and development in the adult., J Mol Endocrinol, 24, 297, 10.1677/jme.0.0240297 · DOI · Paper page
- Sorenson, 1987, Prolactin (in vitro) decreases the glucose stimulation threshold, enhances insulin secretion, and increases dye coupling among islet B cells., Endocrinology, 121, 1447, 10.1210/endo-121-4-1447 · DOI
- Bruning, 1997, Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles., Cell, 88, 561, 10.1016/S0092-8674(00)81896-6 · DOI · Paper page
- Lee, 1989, Compensatory adaption to partial pancreatectomy in the rat., Endocrinology, 124, 1571, 10.1210/endo-124-3-1571 · DOI
- Creutzfeldt, 1985, New developments in the incretin concept., Diabetologia, 28, 565, 10.1007/BF00281990 · DOI · Paper page
- Schirra, 1996, Gastric emptying and release of incretin hormones after glucose ingestion in humans., J Clin Invest, 97, 92, 10.1172/JCI118411 · DOI · Paper page
- Ebert, 1987, Gastrointestinal peptides and insulin secretion., Diabetes Metab Rev, 3, 1, 10.1002/dmr.5610030101 · DOI
- Finegood, 1995, Dynamics of β-cell mass in the growing rat pancreas. Estimation with a simple mathematical model., Diabetes, 44, 249, 10.2337/diab.44.3.249 · DOI · Paper page
- Bollag, 2000, Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors., Endocrinology, 141, 1228, 10.1210/endo.141.3.7366 · DOI · Paper page
- Irwin, 2004, Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice., Biol Chem, 385, 845, 10.1515/BC.2004.110 · DOI · Paper page
- Tseng, 1996, Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat., J Clin Invest, 98, 2440, 10.1172/JCI119060 · DOI · Paper page
- Kieffer, 1999, The glucagon-like peptides., Endocr Rev, 20, 876, 10.1210/edrv.20.6.0385 · DOI · Paper page
- Bullock, 1996, Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide- 1 receptor., Endocrinology, 137, 2968, 10.1210/endo.137.7.8770921 · DOI · Paper page
- Nakagawa, 2004, Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells., Auton Neurosci, 110, 36, 10.1016/j.autneu.2003.11.001 · DOI · Paper page
- Gromada, 1998, Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic β-cells by both proximal and distal regulatory steps in stimulus-secretion coupling., Diabetes, 47, 57, 10.2337/diab.47.1.57 · DOI · Paper page
- Wang, 1997, Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats., J Clin Invest, 99, 2883, 10.1172/JCI119482 · DOI · Paper page
- Burcelin, 2001, Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor., Diabetes, 50, 1720, 10.2337/diabetes.50.8.1720 · DOI · Paper page
- Buteau, 2003, Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor., Diabetes, 52, 124, 10.2337/diabetes.52.1.124 · DOI · Paper page
- De Leon, 2003, Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy., Diabetes, 52, 365, 10.2337/diabetes.52.2.365 · DOI · Paper page
- Pederson, 1998, Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor −/− mice., Diabetes, 47, 1046, 10.2337/diabetes.47.7.1046 · DOI · Paper page
- Falko, 1975, Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man., J Clin Endocrinol Metab, 41, 260, 10.1210/jcem-41-2-260 · DOI · Paper page
- Ross, 1978, Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects., Diabetes, 27, 327, 10.2337/diab.27.3.327 · DOI · Paper page
- Hansen, 2004, Neural regulation of glucagon-like peptide-1 secretion in pigs, Am J Physiol Endocrinol Metab, 287, E939, 10.1152/ajpendo.00197.2004 · DOI · Paper page
- Rocca, 1999, Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion., Endocrinology, 140, 1687, 10.1210/endo.140.4.6643 · doi:10.1210/endo.140.4.6643 · Paper page
- Vilsboll, 2001, Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients., Diabetes, 50, 609, 10.2337/diabetes.50.3.609 · DOI · Paper page
- Hansen, 1999, Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine., Endocrinology, 140, 5356, 10.1210/endo.140.11.7143 · DOI · Paper page
- Gault, 2005, Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes., Diabetes, 54, 2436, 10.2337/diabetes.54.8.2436 · DOI · Paper page
- Xie, 2007, Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass., Bone, 40, 1352, 10.1016/j.bone.2007.01.007 · DOI · Paper page
- Schirra, 2006, Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans., Gut, 55, 243, 10.1136/gut.2004.059741 · DOI · Paper page
- Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 273, E981
- D'Alessio, 1994, Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal., J Clin Invest, 93, 2263, 10.1172/JCI117225 · DOI · Paper page
- Egan, 2002, Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state., J Clin Endocrinol Metab, 87, 3768, 10.1210/jcem.87.8.8743 · doi:10.1210/jcem.87.8.8743 · Paper page
- Krarup, 1988, Immunoreactive gastric inhibitory polypeptide., Endocr Rev, 9, 122, 10.1210/edrv-9-1-122 · DOI · Paper page
- Orskov, 1991, Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine., J Clin Invest, 87, 415, 10.1172/JCI115012 · DOI · Paper page
- Fukase, 1995, Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy., Acta Diabetol, 32, 165, 10.1007/BF00838486 · DOI
- Vaag, 1996, Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)–evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins., Eur J Endocrinol, 135, 425, 10.1530/eje.0.1350425 · DOI · Paper page
- Toft-Nielsen, 2001, Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients., J Clin Endocrinol Metab, 86, 3717, 10.1210/jcem.86.8.7750 · DOI · Paper page
- Knop, 2007, Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?, Diabetes, 56, 1951, 10.2337/db07-0100 · DOI · Paper page
- Ryskjaer, 2006, Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake., Eur J Endocrinol, 155, 485, 10.1530/eje.1.02221 · DOI · Paper page
- O'Donovan, 2004, Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes., J Clin Endocrinol Metab, 89, 3431, 10.1210/jc.2004-0334 · DOI · Paper page
- Elahi, 1994, The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects., Regul Pept, 51, 63, 10.1016/0167-0115(94)90136-8 · DOI · Paper page
- Krarup, 1987, Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus., Metabolism, 36, 677, 10.1016/0026-0495(87)90153-3 · DOI
- Meier, 2005, Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes., Diabetologia, 48, 1872, 10.1007/s00125-005-1863-7 · DOI
- Meier, 2004, Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects, Diabetes, 53, S220, 10.2337/diabetes.53.suppl_3.S220 · DOI · Paper page
- Rachman, 1996, Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM., Diabetes, 45, 1524, 10.2337/diab.45.11.1524 · DOI
- Rachman, 1997, Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM., Diabetologia, 40, 205, 10.1007/s001250050664 · DOI · Paper page
- Ahren, 1997, Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus., J Clin Endocrinol Metab, 82, 473
- Dor, 2006, β-Cell proliferation is the major source of new pancreatic β cells., Nat Clin Pract Endocrinol Metab, 2, 242, 10.1038/ncpendmet0187 · DOI
- Teta, 2007, Growth and regeneration of adult β cells does not involve specialized progenitors., Dev Cell, 12, 817, 10.1016/j.devcel.2007.04.011 · DOI · Paper page
- Skoglund, 2000, Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element., Diabetes, 49, 1156, 10.2337/diabetes.49.7.1156 · DOI · Paper page
- Wang, 2001, Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic β-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism., Endocrinology, 142, 1820, 10.1210/endo.142.5.8128 · DOI · Paper page
- Holz, 2006, Cell physiology of cAMP sensor Epac., J Physiol, 577, 5, 10.1113/jphysiol.2006.119644 · DOI · Paper page
- Buteau, 2001, Protein kinase Cζ activation mediates glucagon-like peptide-1-induced pancreatic β-cell proliferation., Diabetes, 50, 2237, 10.2337/diabetes.50.10.2237 · DOI · Paper page
- Wang, 2002, Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice., Diabetologia, 45, 1263, 10.1007/s00125-002-0828-3 · DOI · Paper page
- Wang, 2005, Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells., Diabetologia, 48, 720, 10.1007/s00125-005-1692-8 · DOI
- Bregenholt, 2005, The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro., Biochem Biophys Res Commun, 330, 577, 10.1016/j.bbrc.2005.03.013 · DOI · Paper page
- Lawrence, 2002, NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1., Diabetes, 51, 691, 10.2337/diabetes.51.3.691 · DOI · Paper page
- Heit, 2006, Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function., Nature, 443, 345, 10.1038/nature05097 · DOI · Paper page
- Hui, 2001, Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells., Diabetes, 50, 785, 10.2337/diabetes.50.4.785 · DOI · Paper page
- Bulotta, 2002, Cultured pancreatic ductal cells undergo cell cycle re-distribution and β-cell-like differentiation in response to glucagon-like peptide-1., J Mol Endocrinol, 29, 347, 10.1677/jme.0.0290347 · DOI · Paper page
- Abraham, 2002, Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin- producing cells., Endocrinology, 143, 3152, 10.1210/endo.143.8.8973 · DOI · Paper page
- Gomez, 2002, cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic β-cells., J Biol Chem, 277, 48146, 10.1074/jbc.M209165200 · DOI · Paper page
- Stoffers, 2000, Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas., Diabetes, 49, 741, 10.2337/diabetes.49.5.741 · DOI · Paper page
- Xu, 1999, Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats., Diabetes, 48, 2270, 10.2337/diabetes.48.12.2270 · DOI · Paper page
- Hui, 2003, Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway., Endocrinology, 144, 1444, 10.1210/en.2002-220897 · DOI · Paper page
- Pospisilik, 2002, Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats., Diabetes, 51, 943, 10.2337/diabetes.51.4.943 · DOI · Paper page
- Doyle, 2007, Mechanisms of action of glucagon-like peptide 1 in the pancreas., Pharmacol Ther, 113, 546, 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
- Perfetti, 2000, Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats., Endocrinology, 141, 4600, 10.1210/endo.141.12.7806 · doi:10.1210/endo.141.12.7806 · Paper page
- Soltani, 2007, In vivo expression of GLP-1/IgG-Fc fusion protein enhances β-cell mass and protects against streptozotocin-induced diabetes., Gene Ther, 14, 981, 10.1038/sj.gt.3302944 · DOI
- Tourrel, 2001, Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age., Diabetes, 50, 1562, 10.2337/diabetes.50.7.1562 · DOI · Paper page
- Sharma, 2006, Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes., Diabetologia, 49, 1247, 10.1007/s00125-006-0251-2 · DOI
- Suen, 2006, In vivo treatment with glucagon-like peptide 1 promotes the graft function of fetal islet-like cell clusters in transplanted mice., Int J Biochem Cell Biol, 38, 951, 10.1016/j.biocel.2005.08.005 · doi:10.1016/j.biocel.2005.08.005
- Wideman, 2006, Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1)., Proc Natl Acad Sci USA, 103, 13468, 10.1073/pnas.0600655103 · DOI · Paper page
- Ghofaili, 2007, Effect of exenatide on β cell function after islet transplantation in type 1 diabetes., Transplantation, 83, 24, 10.1097/01.tp.0000251379.46596.2d · DOI · Paper page
- Amiranoff, 1984, Functional GIP receptors in a hamster pancreatic β cell line, In 111: specific binding and biological effects., Biochem Biophys Res Commun, 123, 671, 10.1016/0006-291X(84)90281-X · DOI
- Kashima, 2001, Critical role of cAMP-GEFII–Rim2 complex in incretin-potentiated insulin secretion., J Biol Chem, 276, 46046, 10.1074/jbc.M108378200 · DOI · Paper page
- Trumper, 2001, Glucose-dependent insulinotropic polypeptide is a growth factor for β (INS-1) cells by pleiotropic signaling., Mol Endocrinol, 15, 1559
- Ehses, 2003, Glucose-dependent insulinotropic polypeptide promotes β-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase., Endocrinology, 144, 4433, 10.1210/en.2002-0068 · DOI · Paper page
- Trumper, 2002, Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in β (INS-1)-cells., J Endocrinol, 174, 233, 10.1677/joe.0.1740233 · DOI · Paper page
- Conarello, 2003, Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance., Proc Natl Acad Sci USA, 100, 6825, 10.1073/pnas.0631828100 · DOI · Paper page
- Amori, 2007, Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis., JAMA, 298, 194, 10.1001/jama.298.2.194 · DOI · Paper page
- Harder, 2004, The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes., Diabetes Care, 27, 1915, 10.2337/diacare.27.8.1915 · DOI · Paper page
- Kolterman, 2005, Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus., Am J Health Syst Pharm, 62, 173, 10.1093/ajhp/62.2.173 · DOI · Paper page
- Edwards, 2001, Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers, Am J Physiol Endocrinol Metab, 281, E155, 10.1152/ajpendo.2001.281.1.E155 · DOI · Paper page
- Egan, 2002, The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes., J Clin Endocrinol Metab, 87, 1282, 10.1210/jcem.87.3.8337 · doi:10.1210/jcem.87.3.8337 · Paper page
- Degn, 2004, Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia., Diabetes, 53, 2397, 10.2337/diabetes.53.9.2397 · DOI · Paper page
- Kolterman, 2003, Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes., J Clin Endocrinol Metab, 88, 3082, 10.1210/jc.2002-021545 · DOI · Paper page
- Zinman, 2007, The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial., Ann Intern Med, 146, 477, 10.7326/0003-4819-146-7-200704030-00003 · DOI · Paper page
- Buse, 2007, Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials., Clin Ther, 29, 139, 10.1016/j.clinthera.2007.01.015 · DOI · Paper page
- Juhl, 2002, Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes., Diabetes, 51, 424, 10.2337/diabetes.51.2.424 · DOI · Paper page
- Chang, 2003, The GLP-1 derivative NN2211 restores β-cell sensitivity to glucose in type 2 diabetic patients after a single dose., Diabetes, 52, 1786, 10.2337/diabetes.52.7.1786 · DOI · Paper page
- Madsbad, 2004, Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial., Diabetes Care, 27, 1335, 10.2337/diacare.27.6.1335 · DOI · Paper page
- Kim, 2007, Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes., Diabetes Care, 30, 1487, 10.2337/dc06-2375 · DOI · Paper page
- Aschner, 2006, Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes., Diabetes Care, 29, 2632, 10.2337/dc06-0703 · DOI · Paper page
- Rosenstock, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study., Clin Ther, 28, 1556, 10.1016/j.clinthera.2006.10.007 · DOI · Paper page
- Zhang, 2007, Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes., Diabetologia, 50, 1900, 10.1007/s00125-007-0737-6 · DOI
- Patriti, 2007, How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and β-cell function in Goto-kakizaki rats through an enhanced proglucagon gene expression and L-cell number., Surgery, 142, 74, 10.1016/j.surg.2007.03.001 · DOI
- Gedulin, 2005, Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight., Endocrinology, 146, 2069, 10.1210/en.2004-1349 · DOI · Paper page
- Mu, 2006, Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes., Diabetes, 55, 1695, 10.2337/db05-1602 · DOI · Paper page
- Reimer, 2002, Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice., Eur J Endocrinol, 146, 717, 10.1530/eje.0.1460717 · DOI · Paper page
Cited by
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Emerging Role of cAMP/AMPK Signaling
Aslam, M., & Ladilov, Y. (2022) · Cells · doi:10.3390/cells11020308 · Cited by 241
“Glucagon-like peptide-1 (GLP-1) mimetics and GLP-1 receptor (GLP-1r) agonists are widely used drugs for glycemic control in type 2 diabetes [102].”
BackgroundCauses and cures for endoplasmic reticulum stress in lipotoxic β ‐cell dysfunction
Cnop, M., Ladrière, L., Igoillo‐Esteve, M., Moura, R. F., & Cunha, D. A. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01279.x · Cited by 150
D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1135 · Cited by 99
“1% cross-reactivity with GIP[3–42], the product of DPP-4.”
BackgroundSelf-citation
Metadata
- Authors
- Salehi, M., Aulinger, B. A., & D'Alessio, D. A.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2008-02-21
- Volume
- 29
- Issue
- 3
- Pages
- 367-379
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2109432892
- Cited by
- 109
- References
- 48
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins. https://app.cochat.ai/papers/10.1210/er.2007-0031
- The paper
- Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008). Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins. Endocrine Reviews. https://doi.org/10.1210/er.2007-0031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.